A Phase 3 Trial of JKN2401 Injection in COPD

Summary

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous JKN2401 Injection in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Timeline

Start

2026-03

Primary completion

2027-09

Completion

2027-11

Drugs

Indications